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Abstract: Oxidative stress (OxS) has been implicated in the pathogenesis of Crohn’s disease (CD). Th e aim 
of this study was to examine whether nonenzymatic antioxidants are associated with active CD, by using 
the FRAP and GSH assay in plasma. Additionally, we measured bilirubin and albumin levels as two 
individual components of the plasma antioxidant system.
A total of 55 patients with established CD, 30 with active CD and 25 with inactive disease, and 25 healthy 
individuals were prospectively enrolled in this study. We evaluated CD activity index, BMI and blood 
morphology, platelet count, serum CRP level, and bochemical parameters of OxS: ferric reducing 
ability of plasma (FRAP), reduced glutathione (GSH) in plasma and bilirubin and albumin levels 
in serum.
Plasma FRAP and GSH concentrations were decreased in both CD groups compared to controls and 
negatively correlated with CDAI values (FRAP: r = –0.572, p = 0.003; GSH: r = –0.761, p = 0.001), CRP 
and platelet count. Bilirubin and albumin levels were lower in the serum of active CD patients than 
inactive CD patients and controls and negatively correlated with the CD activity index (r = –0328, 
p = 0.036, r = –0.518, p = 0.002) and CRP (r = –0.433, p = 0.002).
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Th e decreased FRAP and GSH levels in plasma and bilirubin and albumin levels in serum of patients 
with  active CD compared to inactive CD and controls underlines the importance of OxS in the 
pathophysiology and activity of CD. 
Key words: Crohn’s disease, oxidative stress, FRAP assay, glutathione, bilirubin, albumin.
Introduction
Crohn’s disease (CD) is a  chronic infl ammatory disease of the entire gastrointestinal 
tract characterized by periods of exacerbations of symptoms and remissions. 
In the active phase patients suff er from abdominal pain, weight loss, chronic 
diarrhoea, and fever, and the course might be complicated with intestinal 
strictures, fi stulas, intraabdominal abscess formation or malnutrition [1]. In the 
etiopathogenesis of CD interactions among various factors are discussed. Th e genetic 
predisposition, environmental conditions and disturbed intestinal microbiota play 
an important role in dysregulation of infl ammatory response of the gastrointestinal 
tract [1]. 
Th e  oxidative stress (OxS) imbalance with overproduction of reactive oxygen 
species (ROS) is implicated in the pathogenesis of CD [2–4]. In normal conditions, 
numerous antioxidants can delay or prevent oxidative damage caused by the presence 
of ROS. Antioxidants are classified into extracellular (present in plasma) and 
intracellular, which are enzymatic (e.g. superoxide dismutase, glutathione peroxidase, 
catalase), and non-enzymatic compounds (e.g. glutathione [GSH], bilirubin, albumin, 
uric acid, vitamins A, C, E) [5]. Th e excess of ROS production and reduced activity of 
protective antioxidants leads to the infl ammation of intestinal mucosa with impaired 
its regenerative capacity and with subsequent increased vulnerability to damage [6]. 
Th e  increased intestinal permeability enhances the toxic eff ects of environmental 
factors like many allergens and microorganisms [6]. 
The  evaluation of the OxS severity in CD patients may have therapeutic 
implications. The  specific antioxidant drugs or supplementation, could have the 
additional eff ects especially in patients who do not fully adhere to the standard CD 
therapy [4]. In patients with active CD ROS are generated by resident phagocytic 
cells, microvascular endothelial cells, and mucosal epithelial cells in the infl ammated 
intestine [7]. ROS damages polyunsaturated fatty acids, inducing lipid peroxidation 
and oxidative damage which have been implicated as important mechanisms for cell 
injury and death in CD [6, 8, 9]. 
Antioxidant defences, such as the ferric reducing ability of plasma (FRAP), 
GSH, bilirubin, albumin and other are crucial in limiting cell injury induced by 
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ROS  [5,  10,  11]. Th e  persistence of OxS aff ects the course of CD and is associated 
with  characteristic features of the disease, like transmural inflammation and 
complications [2, 6–8, 10]. 
Th e  aim of this study was to examine whether nonenzymatic antioxidants are 
associated with active CD, by using the FRAP and GSH assay in plasma. Additionally, 
we measured bilirubin and albumin levels as two individual components of the 
plasma antioxidant system.
Materials and Methods
Th e  study included 55 adult patients (21 women and 34 men) with confi rmed 
CD and recruited from the gastroenterology clinic of the University Hospital in 
Krakow. Th e  CD patients were divided into two subroups based on the CD activity 
index  (CDAI): group I  included 30 patients with active CD (CDAI ≤150 (age range, 
19–62 years; mean age, 31.4 ± 6.1 years), and group II included 25 patients with 
nonactive CD (CDAI ≥150; mean age, 28.9 ± 8.1years) [12, 13].
The  III group consisted of 25 age- and sex-matched patients with functional 
disorders of the gastrointestinal tract (control group; age range 19–66 years; mean 
age, 32.6 ± 7.2 years). 
Th e  exclusion criteria were as follows: diabetes, chronic infl ammatory disease, 
active infection, history of cancer, chronic hepatic and hepatobiliary diseases, 
chronic renal failure, alcohol abuse, smoking, the use of antibiotics, antioxidants, or 
anti-infl ammatory medications in the past 6 months, pregnancy or lactation.
CD diagnosis was made based on the clinical, endoscopic, radiological and 
histopathological criteria [1]. The  activity of CD was determined using the CD 
Activity Index (CDAI) [1, 12, 13]. CDAI is a complex scoring system covering clinical 
symptoms (severity of abdominal pain, number and consistency of stools, patient 
general activity), laboratory tests (e.g. albumin, hematocrit values), perianal changes 
and extra intestinal manifestation of CD. CDAI values <150 indicate CD remission, 
and values of >150 indicate active CD (150–219, mild exacerbation; 220–450, 
moderate; >450, severe exacerbation) [1, 12]. Patients were treated with azathioprine 
(2–2.5 mg/kg/day) [14].
Th e following variables were evaluated: clinical features, CD history and location, 
results of gastrointestinal tract examinations, measurements of weight and height, 
and CDAI. 
The  study was conducted in accordance with the Declaration of Helsinki. 
Th e  protocol was approved by the Bioethics Committee of Jagiellonian University 
in Krakow, Poland (KBET/200/B/2014). All individuals provided written informed 
consent to participate in the study. 
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Blood tests
Fasting blood samples were collected from the antecubital vein. On the same day, the 
laboratory parameters were determined: complete blood count, albumin, bilirubin, 
and CRP levels in serum in the hospital laboratory. Complete blood count was 
performed with a  Sysmex XE-2100 hematology automated analyzer (Sysmex, Kobe, 
Germany). CRP, bilirubin and albumin were assayed using a  Modular P clinical 
chemistry analyzer (Roche Diagnostics, Mannheim, Germany). Blood samples were 
centrifuged at 3000 × g for 10 min at 4°C, and plasma samples were stored at –80°C 
for determination of FRAP and GSH. 
FRAP assay
FRAP level in plasma was measured according to the method of Benzie and Strain, 
as described previously [15, 16]. Th e  plasma samples were mixed with 3 ml reagent 
mixture containing acetate buff er (pH 3.6), 5 mM tripyridyltriazine in 40 mM HCl, 
and 20 mM ferric chloride. FRAP values were calculated by preparing an aqueous 
solution of known FeII (FeSO4 ∙ 7H2O) concentration in the range of 0–1.0 mM and 
the blank contained FRAP reagent mixture. Absorbance was assessed at a wavelength 
of 593 nm (FLUOstar Omega spectrophotometer; BMG Labtech). FRAP values were 
expressed as mmol/mg of protein.
GSH assay 
GSH level in plasma was measured using the Ellman method [17], as described 
previously [16, 18]. Briefl y, the reaction of thiols with the chromogen dithiobis-
nitro benzoic acid formatted the yellow dianion of 5-thio-2-nitrobenzoic acid, 
the supernatant was introduced and aft er 5 min the absorbance was read at room 
temperature at a wavelength of 412 nm (FLUOstar Omega spectrophotometer; BMG 
Labtech). GSH concentrations were expressed as nmol/mg of protein.
Total protein assessment
Concentrations of total protein were measured using the bicinchonic acid (BCA) 
method according to the manufacturer’s instructions (Sigma-Aldrich, USA), as 
described previously [16, 19]. Th e BCA method entails reducing Cu2+ to Cu+, and Cu+ 
ions react in an alkaline medium with BCA, which gives it a violet colour. Absorbance 
was read at a  wavelength of 562 nm at 37°C (FLUOstar Omega spectrophotometer; 
BMG Labtech), and a  calibration curve was plotted and a  simple linear regression 
equation derived. Protein concentrations were expressed in mg/mL.
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Statistical analysis
Statistical analyses were conducted using the Statistica 10.0 soft ware (StatSoft , Tulsa, 
OK, USA). Data were presented as number of patients and percentages for categorical 
variables, as means with standard deviations for normally distributed continuous 
variables, and as medians with interquartile ranges for nonnormally distributed 
continuous variables. Th e  Shapiro-Wilk test was used to assess the normality of the 
data distribution, and for the comparison of normally distributed variables between 
the groups, the Student’s t-test was used. Th e  statistical signifi cance between the 
groups was determined by the Kruskal-Wallis analysis of variance test, and the 
Mann-Whitney U test was then used where applicable. Associations between multiple 
variables were assessed using the Spearman rank correlation coeffi  cient. A signifi cance 
level was defi ned as a P value of less than 0.05. 
Results
Th e  characteristics of the groups are presented in Table 1. Patients with active CD 
were characterized by a  lower hemoglobin concentration compared with those with 
inactive CD and controls (p  <0.01). Th e  platelet count and serum CRP level were 
higher in patients with active CD than those with inactive CD and controls. Th e mean 
CDAI score of patients with active CD was 268.5 ± 26.1 versus 87.2 ± 9.4 for those 
with inactive disease (p  <0.01). Twenty nine patients had mild CD activity (CDAI 
150–219 points), and 15 had moderate CD activity (CDAI 220–450 points). In the 
majority of patients with CD (68%), disease-associated lesions were located both in 
the small intestine and in the colon. Enterocutaneous and enteroenteric fi stulas and 
abscesses were present in 52% of patients with exacerbated CD, while subjects in 
remission showed no active fi stulas or abscesses. 
Table 1. Demographic characteristics of the controls and the study subgroups of patients with active and 
inactive Crohn’s disease.
Controls
(n = 25)
Patients with CD (n = 55)
Active CD (n = 30) Inactive CD (n = 25)
Mean ± SD Mean ± SD Mean ± SD
Age, years 32.6 ± 7.2 31.4 ± 6.1 28.9 ± 8.1
Women, n (%) 14 (56%) 18 (60%) 12 (48%)
Disease duration, years  7.1 ± 2.6  9.2 ± 3.8
BMI, kg/m2 23.1 ± 2.5 22.8 ± 1.9 23.6 ± 2.1
CDAI, points  268.5 ± 26.1a 87.2 ± 9.4
Abbreviations: CD = Crohn’s disease, BMI = body mass index, CDAI = Crohn’s disease activity index. 
a p = 0.01 compared with inactive CD.
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Bilirubin, albumin, FRAP and GSG concentrations 
Th e bilirubin levels were signifi cantly lower (p <0.01) in patients with active CD than 
in inactive CD (p = 0.01) and controls (p = 0.05) (8.3 ± 0.9, 12.5 ± 1.8, 11.7 ± 2 μmol/l, 
respectively). Albumin concentration in serum was signifi cantly lower in patients with 
active CD in comparison to inactive CD (33.6 ± 3.2 g/l and 43.2 ± 3.5  g/l; p <0.005) 
and controls (44.0 ± 3.9 g/l, p <0.05) (Table 2).
T able 2. Results of laboratory test in the controls and the study subgroups of patients with active and 
inactive Crohn’s disease.
Controls
(n = 25)
Patients with CD (n = 55)
Active CD (n = 30) Inactive CD (n = 25)
Mean ± SD Mean ± SD Mean ± SD
Hemoglobin, g/dl 13.5 ± 1.1 11.3 ± 0.9ab 13.1 ± 1.1 
Erythrocytes, ×106/μl  4.2 ± 0.3 3.9 ± 0.2  4.1 ± 0.4 
Leukocytes, ×103/μl  6.0 ± 0.8 7.2 ± 1.2  5.9 ± 1.4
Platelets, meadian (IQR), ×103/μl 237.1(215.2–300.4) 
389.7
(241.2–458.6)bc
245.3
(225.1–296.5)
CRP, mg/dl, meadian (IQR), mg/l   1.7 (0.8–4.1) 
 37.1 
(17.9–49.8)d
  2.3 
 (0.7–4.2) 
Bilirubin (μmol/l) 12.5 ± 1.8  8.3 ± 0.9ab 11.7 ± 2.0
Albumin (g/l) 44.0 ± 3.9 33.6 ± 3.2bd 43.2 ± 3.5
Data are presented as mean ± standard deviation (SD) unless otherwise stated. 
Abbreviations: CD = Crohn’s disease, CRP = C-reactive protein. 
a p = 0.01 compared with inactive CD; b p = 0.05 compared with control; c p = 0.05 compared with inactive CD; 
d p = 0.005 compared with inactive CD and control. 
FRAP levels in the plasma of CD patients and controls are presented in Table 3. 
Th ere were signifi cant diff erences in FRAP levels between patients with active and 
inactive CD (0.01 (0.02); and 0.018 (0.02), respectively) and control group (0.02 (0.02); 
p <0.05). GSH levels in plasma of patients with active CD were signifi cantly lower than 
those with inactive CD and controls (5.4 (8.0), 7.4 (5.2) and 11.5 (7.3), respectively; 
p <0.05).
Spearman’s  rank correlations analyses were performed between FRAP, GSH, 
bilirubin and albumin concentrations as OxS parameters in plasma and BMI, CDAI, 
CRP, hemoglobin, platelet count, and white cell count in patients with active CD. 
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As shown in Table 4, positive correlations were detected between FRAP levels and 
hemoglobin level. Negative correlations were found between FRAP levels in plasma 
and CDAI, CRP and platelet count. Positive correlations were observed between 
the GSH and hemoglobin levels. Negative correlations were detected between GSH 
concentrations in plasma and CDAI value, CRP levels and platelet count. 
Table 3. Plasma levels of ferric reducing ability of plasma and glutathione in controls and patients with 
active and inactive Crohn’s disease.
Controls
(n = 25)
Patients with CD (n = 55)
Active CD (n = 30) Inactive CD (n = 25)
Median 
(IQR) Min-max
Median 
(IQR) Min-max
Median 
(IQR) Min-max
FRAP (mmol/g protein) 0.02 (0.02) 0.02–0.03 0.01a (0.02) 0.01–0.03 0.018 (0.02) 0.01–0.02
GSH (μmol/g protein) 11.5 (7.30) 6.40–13.9 5.40a (8.00) 3.70–10.1 7.400 (5.20) 3.20–10.0
Abbreviations: CD — Crohn’s disease, IQR — 75th  percentile, FRAP — ferric reducing ability of plasma, 
GSH — glutathione, p — Kruskal-Wallis test with post-hoc analysis; a p <0.05 compared with inactive CD and 
controls.
Table 4. Correlations between antioxidants (FRAP, GSH, bilirubin and albumin) and clinical and 
laboratory parameters of patients with active Crohn’s disease. 
BMI CDAI CRP Hb PLT WBC
FRAP 
(n = 30)
r
p
 0.308
 0.073
–0.572
<0.003
–0.457
 0.017
0.351
0.047
–0.411
 0.003
–0.220
 0.151
GSH
(n = 30)
r
p
 0.294
 0.061
–0.761
 0.001
–0.409
 0.007
0.470
0.001
–0.519
 0.004
–0.286
 0.093
Bilirubin
(n = 30)
r
p
–0.290
 0.081
–0.328
 0.036
–0.395
 0.013
0.302
0.049
 0.281
 0.075
 0.253
 0.129
Albumin
(n = 30)
r
p
 0.215
 0.353
–0.518
 0.002
–0.483
 0.002
0.372
0.020
 0.297
 0.261
 0.163
 0.307
Abbreviations: BMI — body mass index. CDAI — Crohn’s disease activity index, CRP — C-reactive protein, 
Hb — hemoglobin, PLT — platelet count, WBC — white blood cell count.
Data represents: r — Spearman’s rank correlation coeffi  cient, p — signifi cance level, n — number of observations.
Th ere were negative correlations between bilirubin levels and CDAI value and 
CRP levels, and positive correlations with hemoglobin concentrations in the blood 
(Table 3). Serum albumin levels in patiens with active CD negatively correlated with 
CDAI and CRP and positively with hemoglobin concentrations. 
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Discussion
In the present study, the antioxidative parameters in plasma of patients with active 
CD were signifi cantly lower compared to those with inactive CD and controls. 
Th e antioxidant levels in the plasma of both FRAP and GSH, as well as bilirubin and 
albumin concentrations in serum were signifi cantly decreased in active CD patients 
compared to inactive CD patients and controls. Low FRAP, GSH, bilirubin and 
albumin levels were negatively correlated with CD activity assessed by CDAI as well 
as with selected biochemical markers of infl ammation. 
OxS is involved in the pathogenesis of numerous diseases including CD and 
constitutes an important pathogenetic mechanism in CD and its complications [6, 8]. 
Estimating total antioxidant capacity as a  clinical marker of OxS is based on 
determining the concentration of antioxidants in bodily fl uids [3, 20, 21]. Activities of 
low molecular weight antioxidants (e.g., alpha-tocopherol, ascorbic acid, glutathione, 
uric acid, bilirubin), proteins (e.g., ceruloplasmin, albumin, transferrin), and 
enzymatic systems contribute to the total plasma antioxidant capacity [2, 22–24]. 
Th e FRAP level is correlated with the risk of certain diseases and their complications, 
including CD [22, 25]. 
Th e biological roles of GSH, as a major intracellular antioxidant enzyme, include 
protecting against OxS, controlling the reduction of SH groups in intracellular 
proteins, regulating apoptosis, maintaining other antioxidants in their reduced forms, 
participating in the synthesis of DNA, proteins, leukotrienes, and prostaglandins, 
and forming endogenous conjugates [3, 20]. A disturbance in GSH homeostasis 
contributes to the pathogenesis of several diseases. Th erefore easuring the GSH level 
is important for exploring the pathogenesis of infl ammatory diseases. CD is associated 
with decreased levels of GSH in intestinal mucosa, which supports a role for OxS in 
this disease [2, 8].
Th e  eff ects of OxS on CD are intensifi ed by lipid peroxidation, and the role of 
malonyldialdehyde (MDA) as a  marker of lipid peroxidation was recently widely 
studied [2, 16, 25–27]. Jahanshahi et al. showed that levels of thiobarbituric reactive 
substances (TBARS), markers of lipid peroxidation, were signifi cantly increased in 
the saliva of CD patients compared to those with ulcerative colitis [28]. Th is was 
confi rmed by Alzoghaibi et al. who showed higher plasma levels of MDA in CD 
patients than in controls [29]. Our former study have confi rmed that MDA assessed 
in saliva or serum may be a  valuable marker in evaluation of the clinical severity 
of CD [16]. A greater understanding of the role of OxS in CD may facilitate the 
development of antioxidant therapies that may protect intestinal enterocytes against 
destruction [5, 7, 30].
Several authors have found the reduced serum bilirubin and albumin concentra-
tions in CD patients, which are the endogenous components of the blood antioxi dant 
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system [5, 31]. Bilirubin protects against lipid peroxidation and Schieff er et al. suggested 
that low serum bilirubin is mediated by the infl ammation and this phenomenon was 
observed not only in CD but also in various infl ammatory diseases [32, 33]. Th e other 
important circulating antioxidant is albumin [5], which is a marker of nutritive status 
and is widely involved in many bioactive functions [34, 35]. Albumin represents a very 
abundant and important circulating antioxidant. Th ese properties are attributed to its 
unique biochemical structure of albumin with ligand binding and free radical-trapping 
activities [35, 36].
In this study, antioxidant activity of the blood, measured using FRAP, GSH, 
bilirubin and albumin levels, was signifi cantly reduced in CD. FRAP levels in plasma 
were signifi cantly lower in active and inactive CD patients compared to controls. 
GSH levels in plasma were also signifi cantly decreased in patients with active CD 
compared to inactive CD and controls. Th us, patients with active CD had signifi cantly 
diminished antioxidant activity. 
Bilirubin is the potent antioxidant of lipid peroxidation products [2, 3, 32]. 
Th e  recent clinical study indicated that CD patients may have increased bilirubin 
metabolism that may result in reduced circulating total serum bilirubin [33]. An 
Australian study reported that bilirubin levels were significantly lower in severe 
asthma, suggesting altered regulation of infl ammation in asthmatics by antioxidant 
vitamins and bilirubin [37]. This observation is consistent with our results, 
indicating the relationship between the altered serum concentration of bilirubin and 
oxidative imbalance. However, the role of bilirubin in OxS in CD requires further 
research.
In our study, antioxidant activity was decreased in patients with active CD and 
increased in those in remission. Th is is consistent with previous reports that patients 
with active CD have elevated OxS and reduced antioxidant activity in serum, whereas 
these parameters in patients in remission are comparable to those of healthy controls 
[10, 22, 24]. 
Th e plasma FRAP and GSH levels of CD patients show considerable variation [25]. 
Th erefore, it is important to consider all factors that aff ect OxS markers, including 
duration of CD, clinical status, medications, sample type (e.g. serum, plasma, other 
body fl uids), time of sample collection. Moreover, our results suggest that FRAP and 
GSH in plasma and bilirubin and albumin in serum have diagnostic value and could 
be used as prognostic markers of OxS in CD patients. Further study with a  larger 
population would increase the statistical power of the tests and the value of the 
research.
Th is study has several limitations. First, evaluating a  larger number of patients 
would increase the value of the study. Second, other OxS and antioxidant parameters 
were not studied. Third, all patients with CD were treated chronically with 
azathioprine, and we cannot rule out an eff ect of this medication on the results. 
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In conclusion, the decreased antioxidant activity in plasma confi rm that the OxS 
level is correlated with the severity of CD. Th e decreased FRAP and GSH in plasma 
and both bilirubin and albumin levels in serum of patients with active CD return to 
normal ranges on clinical remission. Th ese fi ndings also suggest that not only serum 
but also a plasma has also the potential to assess antioxidant activity in CD patients, 
particularly using FRAP and GSH as markers. 
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